Core Viewpoint - The article highlights the recruitment of research positions in Professor Shu Yilai's team at Fudan University, focusing on groundbreaking research in gene therapy for hearing loss and the development of clinical applications [1][2]. Group 1: Professor Shu Yilai's Achievements - Professor Shu Yilai has developed gene therapy drugs for hearing loss and led the world's first clinical trial for congenital hearing loss, successfully restoring hearing and speech in multiple patients [1][2]. - His research has been published in prestigious journals such as The Lancet, BMJ, Nature Medicine, and JAMA Neurology, with significant recognition in the scientific community [1][2][3]. - He has received numerous awards, including the 48th ARO "Clinical Science Innovation Award," making him the first Asian scientist to achieve this honor [3]. Group 2: Research Focus and Innovations - The research team focuses on the mechanisms, prevention, and treatment of hearing loss, establishing a leading domestic and internationally advanced research platform [2]. - Key innovations include exploring the pathogenic mechanisms of common deafness genes and developing new strategies for gene therapy and drug delivery to the inner ear [2]. - The team has successfully developed candidate drugs for OTOF mutation-related hearing loss and conducted the first global clinical trial for congenital hearing loss [2]. Group 3: Recruitment Opportunities - The team is recruiting for positions including assistant researchers, postdoctoral researchers, and research assistants, with a focus on candidates with backgrounds in genetics, biology, clinical medicine, and related fields [4][5][11]. - Postdoctoral positions offer competitive salaries ranging from 300,000 to 500,000 CNY annually, with additional research rewards and opportunities for project leadership [8][9][12]. - The research assistant role requires a master's or bachelor's degree in life sciences or clinical medicine, with skills in molecular biology techniques and clinical research experience preferred [11]. Group 4: Research Platform and Resources - The research platform is supported by Fudan University's Biomedical Research Institute and the National Key Laboratory of Medical Neurobiology, providing a rich clinical resource [14]. - The affiliated hospital has a high patient volume, with over 3.29 million outpatient visits and more than 193,000 surgeries annually, making it a significant base for medical research and education [14]. - The hospital has established a gene and cell therapy center, focusing on innovative treatments for hearing loss and other conditions, and has received multiple awards for its research achievements [15][16].